You are here

  • Home
  • Archive
  • Volume 10, Issue 2
  • Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis

Article metrics

Article menu
Immunotherapy biomarkers
Original research
Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis

 

Online download statistics by month:

Online download statistics by month: February 2022 to September 2025

AbstractFullPdf
Feb 202224124775
Mar 2022239241153
Apr 202211712358
May 2022999936
Jun 202213313647
Jul 202210010032
Aug 202211812627
Sep 202211911918
Oct 2022828633
Nov 2022838317
Dec 2022848422
Jan 2023515218
Feb 2023717119
Mar 2023545631
Apr 2023414129
May 202339399
Jun 202330306
Jul 2023545433
Aug 2023414116
Sep 2023313111
Oct 2023191911
Nov 2023484918
Dec 202336369
Jan 2024394030
Feb 2024272718
Mar 2024757559
Apr 2024505026
May 2024929227
Jun 2024555429
Jul 2024666729
Aug 2024414022
Sep 2024525218
Oct 2024565621
Nov 2024323313
Dec 2024454621
Jan 2025464722
Feb 2025848414
Mar 2025343415
Apr 2025808014
May 2025434424
Jun 2025282811
Jul 2025110
Sep 2025110
Total287729141141